12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Company News  |  Other News

GlaxoSmithKline, Humana Inc. endocrine/metabolic news

A class-action suit brought by insurer Humana against GlaxoSmithKline seeking reimbursement for patients treated with GSK's diabetes drug Avandia rosiglitazone will proceed in a district court after the U.S. Supreme Court declined to review the case. Humana filed the class action suit in November 2010 seeking reimbursement for private health insurers that paid for the drug and subsequent healthcare...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >